DNA Therapeutics-Yaohai Biopharmaceutical Co., Ltd.

DNA Therapeutics

Modality

DNA Therapeutics

DNA Therapeutics for Human Use

The primary development focus of naked plasmid therapeutics is angiogenic factors gene therapy. As of now, there are a total of two approved naked plasmid drugs for human use globally: Neovasculgen, launched in Russia in 2011, and Collategene, introduced to the Japanese market in 2019. Several other naked plasmid drugs are currently in the Phase II-III clinical stages. Encoding genes include HGF, VEGF-A, SDF-1 (CXCL12), and among others.

DNA Therapeutics for Animal Use

Different from human medicines, DNA vaccines have been more successful for animal use, including veterinary and pet.

Table 1. Approved naked plasmid DNA in human and animal

Application	Product	Species	Target	Indication	Company	Licensed Date/ Country
Gene therapy	Neovasculgen, Cambiogenplasmid, PI-VEGF165	Human	VEGF-A	CLI, critical limb ischemia	Human Stem Cell Institute	2011/ Russia
Gene therapy	Collategene, beperminogene perplasmid, AMG0001	Human	HGF	CLI, critical limb ischemia	AnGes	2019/Japan
Gene therapy	LifeTideSW5	Swine	Porcine growth hormone-releasing hormone (GHRH)	Increase the number of piglets weaned	VGX Animal Health	2008/Australia
Cancer Immunotherapy	Oncept	Canine	Human tyrosinase	Oral malignant melanoma (OMM)	Merial, Boehringer Ingelheim Animal Health	2010/USA
Antimicrobials	Zelnate	Bovine	CpG motif	Bovine respiratory disease (BRD) due to Mannheimia haemolytica	Bayer Animal Health, Elanco	2015/USA

Yaohai Bio-Pharma Offers One-Stop CDMO Solution for Plasmid DNA

Reference:

[1] Pagliari S, Dema B, Sanchez-Martinez A, Montalvo Zurbia-Flores G, Rollier CS. DNA Vaccines: History, Molecular Mechanisms and Future Perspectives. J Mol Biol. 2023 Dec 1;435(23):168297. doi: 10.1016/j.jmb.2023.168297.

All Categories

DNA Therapeutics

Modality